Hantaan Virus

Hantaan virus (HTNV) is the prototype virus of the genus Orthohantavirus within the family Hantaviridae and the leading cause of hemorrhagic fever with renal syndrome (HFRS) in Asia. First isolated in 1978 from the striped field mouse (Apodemus agrarius) near the Hantaan River in South Korea, this enveloped negative-sense RNA virus remains a significant public health threat, with over 90% of global HFRS cases occurring in China. Unlike most members of the order Bunyavirales, hantaviruses are not arthropod-borne; rather, they are persistently carried by rodent reservoirs and transmitted to humans through aerosolized excreta, saliva, or urine. HTNV infection causes vascular endothelial dysfunction, capillary leakage, and acute kidney injury, with mortality rates ranging from 1% to 15% depending on the viral strain and clinical management. Despite decades of research, no FDA-approved vaccines or specific antiviral therapies are currently available, underscoring the urgent need for deeper understanding of HTNV molecular pathogenesis. This article synthesizes current knowledge on HTNV virology, replication dynamics, and key molecular targets that inform therapeutic and vaccine development.

Figure 1. Hantaan virus overview.

Virus Classification and Genomic Organisation

HTNV belongs to the order Bunyavirales, family Hantaviridae, and genus Orthohantavirus. It is classified as an Old World hantavirus, distinct from New World viruses that cause hantavirus cardiopulmonary syndrome (HCPS) in the Americas. The viral genome consists of three negative-sense, single-stranded RNA segments designated large (L), medium (M), and small (S). The L segment (approximately 6.5 kb) encodes the RNA-dependent RNA polymerase (RdRp), a multifunctional enzyme responsible for viral transcription and genome replication. The M segment (approximately 3.4 kb) encodes a glycoprotein precursor polyprotein that is co-translationally cleaved into two envelope glycoproteins, Gn (formerly G1) and Gc (formerly G2), which form heterodimeric spikes on the virion surface. The S segment (approximately 1.7 kb) encodes the nucleocapsid protein (N), which encapsidates viral RNA to form ribonucleoprotein complexes essential for transcription and replication. The striped field mouse (Apodemus agrarius) serves as the primary reservoir host, maintaining persistent asymptomatic infection while shedding virus in excreta that contaminates human environments.

Virion Structure and Viral Entry

HTNV virions are spherical or pleomorphic, approximately 80-120 nm in diameter, with a characteristic square-shaped surface lattice composed of Gn-Gc heterotetrameric spikes. Each spike comprises four Gn-Gc heterodimers, with Gn forming the globular head domain that shields the class II fusion protein Gc, preventing premature membrane fusion during viral egress. Viral entry into host cells—primarily endothelial cells, macrophages, and dendritic cells—is mediated by Gn binding to cellular receptors, including β3 integrins and the complement regulatory protein CD55. HTNV preferentially utilizes β1 and β3 integrins for attachment, a tropism that contributes to vascular endothelial cell targeting. Following receptor engagement, the virus enters via clathrin-mediated endocytosis, traffics through early and late endosomes, and undergoes pH-dependent membrane fusion triggered by conformational changes in Gc. The ribonucleocapsids are then released into the cytoplasm to initiate transcription and replication.

Immune Evasion and Pathogenesis

HTNV employs multiple strategies to subvert host immunity beyond the RIPK3-mediated JAK/STAT inhibition described above. The virus establishes persistent infection in rodent reservoirs without causing disease, indicating co-evolution of immune modulation strategies. In humans, pathogenic hantaviruses suppress early interferon responses while triggering late hyperinflammation that contributes to vascular leakage. Endothelial cells, the primary targets of infection, respond to HTNV by upregulating adhesion molecules and chemokines that recruit immune cells, but the infected endothelium remains intact, allowing continued viral propagation. The balance between viral immune evasion and host inflammatory responses determines clinical outcomes, with severe disease associated with exaggerated cytokine responses and endothelial dysfunction.

Conclusions

Hantaan virus remains a significant pathogen in Asia and a prototype for understanding hantavirus biology. Recent structural and immunological studies have illuminated key molecular targets—including Gn neutralization epitopes, N protein trafficking mechanisms, host restriction factors such as STING and let-7a, and immune evasion strategies involving RIPK3. These discoveries provide a foundation for developing targeted therapeutics, rationally designed vaccines, and diagnostic tools capable of distinguishing circulating strains. The continued investigation of HTNV-host interactions at the molecular level promises to yield insights applicable not only to HFRS prevention but also to the broader understanding of viral hemorrhagic fevers.

Hantaan Virus Antibody

Hantaan Virus Antigens